Abstract

Although many biotech products are successfully stored in the frozen state, there are cases of degradation of biologicals during freeze storage. These examples are discussed in the Perspective to emphasize the fact that stability of frozen biologicals should not be taken for granted. Frozen-state degradation (predominantly, aggregation) has been linked to crystallization of a cryoprotector in many cases. Other factors, for example, protein unfolding (either due to cold denaturation or interaction of protein molecules with ice crystals), could also contribute to the instability. As a hypothesis, additional freezing-related destabilization pathways are introduced in the paper, that is, air bubbles formed on the ice crystallization front, and local pressure and mechanical stresses due to volume expansion during water-to-ice transformation. Furthermore, stability of frozen biologicals can depend on the sample size, via its impact on the freezing kinetics (i.e., cooling rates and freezing time) and cryoconcentration effects, as well as on the mechanical stresses associated with freezing. We conclude that, although fundamentals of freezing processes are fairly well described in the current literature, there are important gaps to be addressed in both scientific foundations of the freezing-related manufacturing processes and implementation of the available knowledge in practice.

Highlights

  • Freezing is a common unit operation in the production of biopharmaceuticals

  • Many biotech products are successfully stored in the frozen state, there are confirmed cases of freeze-induced instability

  • Several examples of degradation during storage of frozen biologicals are considered in the paper, to stress the fact that frozen-state stability should not be taken for granted, especially if a product is stored at À15C to À25C

Read more

Summary

Introduction

Freezing is a common unit operation in the production of biopharmaceuticals. Most biological drug substances (DS) are stored in the frozen state,[1] while frozen solutions are occasionally used as a drug product (DP) form in early-phase clinical studies. Examples of glass vial breakage as the result of solute þ water crystallization during freeze-drying has been reported for several formulations with crystallizable excipients including, for example, mannitol and NaCl.[60,61,62] Because of the potential impact of a solute crystallization on the manufacturing process and the quality of the finished product, it is essential to understand and monitor crystallization of a solute in any biological drug substance and DP if it is exposed to freeze-thaw or freezedrying. Various aspects of ice nucleation, including controlled ice nucleation in freeze-drying, are discussed in detail elsewhere.[16,64,65] Progression of the crystallization front is a complex process which requires simultaneous heat transfer and solute diffusion and depends on the sample volume and macroscopic and microscopic mixing conditions in a particular location of a sample. Separation of the bottoms of glass vials, which were filled with water, was detected during vacuum-assisted freezing, with ice crystals growing from the surface of the sample

Summary
Findings
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call